Get the Stockscreener App
0.4451
10.48%
-0.0521
After Hours:
.43
-0.0151
-3.39%
Clearside Biomedical Inc stock is traded at $0.4451, with a volume of 1.36M.
It is down -10.48% in the last 24 hours and down -42.19% over the past month.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
See More
Previous Close:
$0.4972
Open:
$0.48
24h Volume:
1.36M
Relative Volume:
1.68
Market Cap:
$34.59M
Revenue:
$8.23M
Net Income/Loss:
$-32.49M
P/E Ratio:
-0.8398
EPS:
-0.53
Net Cash Flow:
$-19.91M
1W Performance:
+31.30%
1M Performance:
-42.19%
6M Performance:
-51.62%
1Y Performance:
-61.96%
1-Day Range:
$0.43
$0.485
1-Week Range:
$0.33
$0.60
52-Week Range:
$0.292
$1.65
Clearside Biomedical Inc Stock (CLSD) Company Profile
Name
Clearside Biomedical Inc
Sector
Industry
Phone
678-270-3631
Address
900 NORTH POINT PARKWAY, ALPHARETTA, GA
Compare CLSD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLSD
Clearside Biomedical Inc
|
0.4451 | 38.64M | 8.23M | -32.49M | -19.91M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.83 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.63 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.79 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
595.19 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.51 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Clearside Biomedical Inc Stock (CLSD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-18-25 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jul-18-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-18-25 | Downgrade | Stifel | Buy → Hold |
| Aug-21-24 | Initiated | Chardan Capital Markets | Buy |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Dec-15-21 | Resumed | Wedbush | Outperform |
| Jul-29-21 | Initiated | H.C. Wainwright | Buy |
| May-13-20 | Initiated | ROTH Capital | Buy |
| Aug-09-19 | Downgrade | Needham | Buy → Hold |
| Nov-05-18 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-05-18 | Downgrade | JP Morgan | Overweight → Underweight |
| Nov-05-18 | Downgrade | Stifel | Buy → Hold |
| Mar-06-18 | Reiterated | Needham | Buy |
| May-25-17 | Initiated | JMP Securities | Mkt Outperform |
| Feb-24-17 | Initiated | JP Morgan | Overweight |
| Nov-10-16 | Reiterated | Needham | Buy |
| Oct-24-16 | Reiterated | Stifel | Buy |
View All
Clearside Biomedical Inc Stock (CLSD) Latest News
Can Clearside Biomedical Inc. Rally Enough to Break EvenInvestment Plan With Growth Optimization Finalized - metal.it
Is it the right time to buy Clearside Biomedical Inc. stockBuild a diversified portfolio for stability - jammulinksnews.com
What are Clearside Biomedical Inc. company’s key revenue driversUnlock your portfolio’s hidden potential - jammulinksnews.com
Does Clearside Biomedical Inc. stock perform well during market downturnsUnlock your portfolio’s full growth potential - jammulinksnews.com
When is Clearside Biomedical Inc. stock expected to show significant growthSmart Portfolio Strategy For Beginners - jammulinksnews.com
What makes Clearside Biomedical Inc. stock price move sharplyFree Capital Allocation Plans - jammulinksnews.com
How strong is Clearside Biomedical Inc. company’s balance sheetBuild a strong portfolio for long-term success - jammulinksnews.com
Should I hold or sell Clearside Biomedical Inc. stock in 2025Unlock market-leading stock analysis - jammulinksnews.com
What is the risk reward ratio of investing in Clearside Biomedical Inc. stockBreakthrough profit margins - jammulinksnews.com
How does Clearside Biomedical Inc. generate profit in a changing economyRapid wealth creation - jammulinksnews.com
Competitive Positioning of Clearside Biomedical Inc.: Is It Leading or LaggingHigh Return Investment Tips - Newser
How Resilient Is Clearside Biomedical Inc. Stock During Economic DownturnsCapital Doubling Tips - Newser
Will Clearside Biomedical Inc. Stock Benefit from AI and Green Energy TrendsLow Risk Trade Timing Signals - Newser
What institutions are buying Clearside Biomedical Inc. stock nowSmart Money Signals - Newser
Clearside Biomedical’s Phase 2b Study on CLS-AX: A New Hope for AMD Treatment - TipRanks
What drives Clearside Biomedical Inc. stock priceFree Real-Time Stock Data - PrintWeekIndia
What analysts say about Clearside Biomedical Inc. stockBreakthrough stock performance - PrintWeekIndia
Why Clearside Biomedical Inc. stock attracts strong analyst attentionFree Stock Market Analysis Courses - Newser
Clearside Biomedical Receives Canadian Approval for XIPERE® to Treat Uveitic Macular Edema via Suprachoroidal Delivery - MSN
Clearside Biomedical Announces Approval of XIPERE® - GlobeNewswire
Clearside Biomedical Inc. Stock Analysis and ForecastConsistent high-yield stocks - Autocar Professional
Clearside Biomedical announces approval of XIPERE in Canada - TipRanks
Is Clearside Biomedical Inc. a good long term investmentExceptional portfolio growth - Autocar Professional
Clearside Biomedical stock soars after Health Canada approves XIPERE By Investing.com - Investing.com Nigeria
Clearside Biomedical stock soars after Health Canada approves XIPERE - Investing.com Australia
Health Canada approves Clearside’s XIPERE for uveitic macular edema - Investing.com
Health Canada approves Clearside’s XIPERE for uveitic macular edema By Investing.com - Investing.com Nigeria
Breakthrough Eye Treatment XIPERE Secures Major Health Canada Approval for Macular Edema - Stock Titan
Clearside exploring options to advance suprachoroidal delivery platform - Eyes On Eyecare
Clearside Biomedical announces plan to explore strategic alternatives to advance its proprietary suprachoroidal space (SCS) delivery platform and promising ophthalmology pipeline - Eyes On Eyecare
Analysts Set Clearside Biomedical, Inc. (NASDAQ:CLSD) Target Price at $4.20 - Defense World
Uncovering the Potential of Clearside Biomedical Inc (CLSD) Stock - investchronicle.com
Clearside Biomedical (NASDAQ:CLSD) Downgraded by Stifel Nicolaus to "Hold" - MarketBeat
Chardan Capital Downgrades Clearside Biomedical (NASDAQ:CLSD) to Neutral - Defense World
Clearside Biomedical Inc Stock (CLSD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.32%
1.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):